Is contrast venography a valid surrogate outcome measure in venous thromboembolism prevention studies? [8]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 5, 2005, Pages 1099-1102

  Segers, A E M ^a,c   Prins, M H ^b   Lensing, A W A ^a   Buller, H R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; BIOLOGICAL MARKER;

HUMAN; INCIDENCE; LETTER; LUNG ANGIOGRAPHY; LUNG EMBOLISM; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; THROMBECTOMY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL; METHODOLOGY; THROMBOEMBOLISM; VEIN THROMBOSIS;

BIOLOGICAL MARKERS; CLINICAL TRIALS; CONTRAST MEDIA; HUMANS; PHLEBOGRAPHY; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 23844556606     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01317.x     Document Type: Letter

References (22)

1. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Andersen FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest 2001; 119: 132S-175S.
2. Rodgers A, MacMahon S. Systematic underestimation of treatment effects as a result of diagnostic test inaccuracy: implications for the interpretation and design of thromboprophylaxis trials. Thromb Haemost 1995; 73: 167-171.
3. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
4. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalibo P, Panfilov S, Eskilson C, Anderson M. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-2496.
5. [No authors listed]. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975; 2: 45-51.
6. Levi M, Peters RJ, Piek JJ, Buller HR. New anticoagulants. Ned Tijdschr Geneeskd 2003; 147: 909-915.
7. Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet 2003; 362: 504-505.
8. Lalourcey L. The design of venous thromboembolism prophylaxis trials: is enoxaparin more effective than fondaparinux? Int J Clin Pract 2003; 57: 289-294.
9. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
10. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-244.
11. Morris GK, Mitchell JR. Evaluation of 1251-fibrinogen test for venous thrombosis in patients with hip fractures: comparison between isotope scanning and necropsy findings. Br Med J 1977; 1: 264-266.
12. Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE, Butcher M, Brant RF, Ghali WA, Bergqvist D, Raskob GE. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135: 858-869.
13. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969; 2: 230-232.
14. Pellegrini VD Jr, Clement D, Lush-Ehmann C, Keller GS, Evarts CM. The John Charnley Award. Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop 1996; 333: 27-40.
15. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-1531.
16. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144.
17. Lensing AW, Buller HR, Prandoni P, Batchelor D, Molenaar AH, Cogo A, Vigo M, Huisman PM, ten Gate JW. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement. Thromb Haemost 1992; 67: 8-12.
18. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-1173.
19. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001 ; 88: 913-930.
20. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337-1342.
21. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282: 771-778.
22. Kearon C. Noninvasive diagnosis of deep vein thrombosis in post-operative patients. Semin Thromb Hemost 2001; 27: 3-8.